Sugi Predict

Sugi Predict / Compounds / SCHEMBL1891367

SCHEMBL1891367

SCHEMBL1891367

NC(Cc1nn[nH]n1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIA2 P42262 5/20 0.50
▸ GRIA1 P42261 4/20 0.50
▸ GRIA3 P42263 4/20 0.50
▸ GRIA4 P48058 4/20 0.50
▸ NAALAD2 Q9Y3Q0 2/20 0.47
▸ KDM6B O15054 1/20 0.47
▸ KDM4A O75164 1/20 0.47
▸ KDM5A P29375 1/20 0.47
▸ GRM1 Q13255 1/20 0.44
▸ SLC7A5 Q01650 2/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ GRIK1 P39086 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1891365 1.00 GRIA2 (0.50) GRIA2GRIA1GRIA3GRIA4NAALAD2
SCHEMBL24251553 0.82 NAALAD2 (0.60) GRIA2GRIA1GRIA3GRIA4NAALAD2
SCHEMBL31696740 0.82 NAALAD2 (0.60) GRIA2GRIA1GRIA3GRIA4NAALAD2
SCHEMBL16017460 0.80 CA12 (0.47) NAALAD2KDM6BKDM4AKDM5ACYP3A4
SCHEMBL24915241 0.77 L3MBTL1 (0.42) GRIA2GRIA1GRIA3GRIA4NAALAD2
SCHEMBL2451002 0.70 SLC7A5 (0.49) GRIA2GRIA1GRIA3GRIA4SLC7A5
SCHEMBL23356093 0.70 SLC7A5 (0.49) GRIA2GRIA1GRIA3GRIA4SLC7A5
SCHEMBL198638 0.70 SLC7A5 (0.49) GRIA2GRIA1GRIA3GRIA4SLC7A5
SCHEMBL15662009 0.69 GRIA1 (0.49) GRIA2GRIA1GRIA3GRIA4SLC7A5
SCHEMBL17059092 0.69 CYP1A2 (0.50) GRIA2GRIA1GRIA3GRIA4SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4508235-A2 PAPB AS A BIMOIETY-DEPENDENT THIOETHER INSTALLATION TOOL University of Utah Research Foundation (US) 2025-02-19 — — EP claimed
EP-4489855-A1 ANTI-GLP1R ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF Regeneron Pharmaceuticals, Inc. (US) 2025-01-15 — — EP claimed
US-20240226225-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. (US) 2024-07-11 — — US claimed
US-20230330254-A1 ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2023-10-19 — — US claimed
WO-2023201372-A2 PAPB AS A BIMOIETY-DEPENDENT THIOETHER INSTALLATION TOOL UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2023-10-19 — — WO claimed
WO-2023173132-A1 ANTI-GLP1R ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2023-09-14 — — WO claimed
WO-2022212698-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. (US) 2022-10-06 — — WO claimed
US-20210221843-A1 EPHA2 AGONISTS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-07-22 — — US claimed
US-20250376709-A1 PAPB AS A BIMOIETY-DEPENDENT THIOETHER INSTALLATION TOOL UNIV UTAH RES FOUND (US) 2025-12-11 — — US disclosed
US-20250277012-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. 2025-09-04 — — US disclosed
US-20250170216-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. 2025-05-29 — — US disclosed
US-20250152658-A1 CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA MERCK SHARP & DOHME LLC (US) 2025-05-15 — — US disclosed
WO-2025085727-A1 PAPB AS A BIMOIETY-DEPENDENT THIOETHER INSTALLATION TOOL BANDARIAN VAHE (US) 2025-04-24 — — WO disclosed
EP-4508235-A2 PAPB AS A BIMOIETY-DEPENDENT THIOETHER INSTALLATION TOOL University of Utah Research Foundation (US) 2025-02-19 — — EP disclosed
US-8551938-B2 NPR-B agonists ALCON RESEARCH, LTD. (US) 2013-10-08 — — US disclosed
US-8546523-B2 NPR-B agonists ALCON RESEARCH, LTD. (US) 2013-10-01 — — US disclosed
US-20110112038-A1 NOVEL NPR-B AGONISTS ALCON RESEARCH, LTD. (US) 2011-05-12 — — US disclosed
EP-0761668-B1 Non-classical antifolates UNIV PRINCETON (US) 2002-01-30 — — EP disclosed
US-5786358-A INHIBITORS OF GLYCINAMIDE RIBONUCLEOTIDE FORMYL TRANSFERASE THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1998-07-28 — — US disclosed
EP-0761668-A2 Non-classical antifolates THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1997-03-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210221843-A1 EPHA2 AGONISTS AND USES THEREOF EPHA2, EPHB2, EPHA6 GRIA2 1910/4885GRIA1 2311/4885GRIA3 2933/4885
US-20250277012-A1 CONJUGATED HEPCIDIN MIMETICS HAMP, VIP, HDGF GRIA2 3703/4885GRIA1 3756/4885GRIA3 3876/4885
US-20230330254-A1 ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF GLP1R, GIPR, GCGR GRIA2 761/4885GRIA1 204/4885GRIA3 694/4885
US-20110112038-A1 NOVEL NPR-B AGONISTS NPR1, NPR3, NPBWR1 GRIA2 486/4885GRIA1 366/4885GRIA3 492/4885
US-20240226225-A1 CONJUGATED HEPCIDIN MIMETICS HAMP, SLC40A1, FTH1 GRIA2 3139/4885GRIA1 2895/4885GRIA3 3423/4885
US-20250170216-A1 CONJUGATED HEPCIDIN MIMETICS HAMP, VIP, HDGF GRIA2 3904/4885GRIA1 3828/4885GRIA3 3868/4885
US-20250152658-A1 CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA IL1R1, IL1A, IL1B GRIA2 3804/4885GRIA1 1720/4885GRIA3 3586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.